OncoMatch/Clinical Trials/NCT05053854
PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours
Is NCT05053854 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Talazoparib for neuroendocrine tumors.
Treatment: Talazoparib — This phase 1 dose-escalation study is designed to evaluate the safety and tolerability of talazoparib in combination with 177Lu-DOTA-Octreotate peptide receptor radionuclide therapy (PRRT) in patients with metastatic pancreatic or midgut neuroendocrine tumour (NET).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Neuroendocrine Tumor
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: peptide receptor radionuclide therapy (177Lu, 111In, 90Y)
Any prior exposure to peptide receptor radionuclide therapy (177Lu, 111In or 90Y labelled)
Cannot have received: PARP inhibitor
Any prior exposure to ... PARPi
Cannot have received: immunotherapy
Any prior exposure to ... immunotherapy
Cannot have received: systemic therapy
Exception: except short acting SSA
another systemic therapy administered in the last 3 weeks (except short acting SSA)
Cannot have received: surgery
Surgery ... within <3 weeks of registration
Cannot have received: radiotherapy
radiotherapy within <3 weeks of registration
Lab requirements
Blood counts
Haemoglobin ≥100 g/L; Absolute neutrophil count ≥1.5x10^9/L; Platelets ≥150 x10^9/L
Kidney function
eGFR ≥ 50 ml/min
Liver function
Total bilirubin ≤1.5 x ULN; AST/ALT ≤2.5 x ULN if no liver metastasis or ≤5 x ULN with liver metastases; Albumin ≥ 30 g/L
adequate bone marrow, hepatic and renal function defined as: Haemoglobin ≥100 g/L; Absolute neutrophil count ≥1.5x109/L; Platelets ≥150 x109/L; Total bilirubin ≤1.5 x ULN; AST/ALT ≤2.5 x ULN if no liver metastasis or ≤5 x ULN with liver metastases; Albumin ≥ 30 g/L; eGFR ≥ 50 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05053854 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior peptide receptor radionuclide therapy, PARP inhibitor, immunotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages